Check the time stamp on this data. Updated AI-Generated Signals for Upar Ultra Risk Parity Etf (UPAR) available here: UPAR.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that the Phase 1a clinical trial for its ...

MNPR-101 is Monopar’s proprietary antibody that targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal ...

Yuntao Wu, Professor, Molecular and Microbiology, School of Systems Biology, College of Science, is studying the structure of dicameric repeats (DR) of PSGL-1, a host protein that inhibits HIV virion ...

The therapy is designed to selectively attack cancer cells by focusing on the urokinase plasminogen activator receptor (uPAR), common in various tumor types. With promising clinical and ...

WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today ...